MX2021002188A - Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende. - Google Patents

Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.

Info

Publication number
MX2021002188A
MX2021002188A MX2021002188A MX2021002188A MX2021002188A MX 2021002188 A MX2021002188 A MX 2021002188A MX 2021002188 A MX2021002188 A MX 2021002188A MX 2021002188 A MX2021002188 A MX 2021002188A MX 2021002188 A MX2021002188 A MX 2021002188A
Authority
MX
Mexico
Prior art keywords
sub
pharmaceutical composition
same
amine derivative
heterocyclic amine
Prior art date
Application number
MX2021002188A
Other languages
English (en)
Inventor
Keuk Chan Bang
Yeon Im Lee
Deok Ki Eom
Joon Seok Park
Wol Young Kim
Youn Jung Yoon
Jaehyun Jung
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Priority claimed from PCT/KR2019/010894 external-priority patent/WO2020045941A1/ko
Publication of MX2021002188A publication Critical patent/MX2021002188A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se refiere a un nuevo derivado de amina heterocíclico representado por la siguiente fórmula química 1 y a una composición farmacéutica que lo comprende, y el compuesto de acuerdo con la presente divulgación puede usarse de manera útil para la prevención o el tratamiento de enfermedades autoinmunitarias o cánceres. Fórmula química 1 (ver Fórmula) en donde, en la fórmula química 1, R1, R2, X1, X2, L, Y, A y B son los mismos que los definidos en la memoria descriptiva.
MX2021002188A 2018-08-27 2019-08-27 Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende. MX2021002188A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20180100359 2018-08-27
KR1020190104641A KR102328682B1 (ko) 2018-08-27 2019-08-26 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
PCT/KR2019/010894 WO2020045941A1 (ko) 2018-08-27 2019-08-27 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
MX2021002188A true MX2021002188A (es) 2021-05-14

Family

ID=69802542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002188A MX2021002188A (es) 2018-08-27 2019-08-27 Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.

Country Status (19)

Country Link
US (1) US20220064155A1 (es)
EP (1) EP3845530A4 (es)
JP (1) JP7162741B2 (es)
KR (1) KR102328682B1 (es)
CN (1) CN112638910B (es)
AU (1) AU2019331328B2 (es)
BR (2) BR122022001938B1 (es)
CA (1) CA3108856C (es)
CL (1) CL2021000421A1 (es)
CO (1) CO2021001849A2 (es)
DO (1) DOP2021000030A (es)
EC (1) ECSP21011232A (es)
MA (1) MA53507A (es)
MX (1) MX2021002188A (es)
PE (1) PE20210417A1 (es)
PH (1) PH12021550329A1 (es)
RU (1) RU2760184C1 (es)
SG (1) SG11202101451QA (es)
TN (1) TN2021000025A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114401722A (zh) * 2019-07-19 2022-04-26 布里奇恩生物科学公司 酪氨酸激酶的抑制剂
BR112022016729A2 (pt) * 2020-02-26 2022-10-11 Daewoong Pharmaceutical Co Ltd Método para preparação de derivados de heterociclicamina
KR20210124569A (ko) * 2020-04-03 2021-10-15 주식회사 하임바이오 암 치료를 위한 신규 화합물 및 이를 포함하는 조성물
CN114605404B (zh) * 2022-03-23 2024-01-05 合肥美诺医药有限公司 一种新型含噻唑类化合物、中间体及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA18829A1 (fr) * 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
DE3905763A1 (de) * 1989-02-24 1990-09-06 Bayer Ag Sulfonylierte azinyliminoheteroazole, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als herbizide
KR20020027635A (ko) 1999-09-10 2002-04-13 폴락 돈나 엘. 티로신 키나제 억제제
EP1318997B1 (en) * 2000-09-15 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20020137755A1 (en) * 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
DE112007002257T5 (de) 2006-09-30 2009-07-30 TK Holdings, Inc., Armada Gaserzeugungsmittelzusammensetzungen
CA2760794C (en) * 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
KR20120034726A (ko) * 2009-06-08 2012-04-12 아브락시스 바이오사이언스, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
WO2011034907A2 (en) * 2009-09-16 2011-03-24 Avila Therapeutics, Inc. Protein kinase conjugates and inhibitors
WO2012035055A1 (en) * 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
KR101682417B1 (ko) 2011-02-25 2016-12-06 주식회사유한양행 다이아미노피리미딘 유도체 및 그의 제조방법
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
CN104114543B (zh) * 2012-01-06 2019-03-15 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
JP2015526520A (ja) * 2012-08-31 2015-09-10 プリンシピア バイオファーマ インコーポレイテッド Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体
US9586931B2 (en) * 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
BR112015027381A8 (pt) * 2013-05-01 2018-01-30 Hoffmann La Roche pirimidinas substituídas por heterocicloalquila ligadas ao c e seus usos
WO2015025197A1 (en) * 2013-08-22 2015-02-26 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
SI3060550T1 (sl) * 2013-10-21 2019-09-30 Merck Patent Gmbh Heteroarilne spojine kot inhibitorji BTK in uporabe le-teh
MY182908A (en) * 2014-01-14 2021-02-05 Millennium Pharm Inc Heteroaryls and uses thereof
WO2016001341A1 (en) * 2014-07-03 2016-01-07 F. Hoffmann-La Roche Ag Sulfonylaminopyridine compounds, compositions and methods of use
US10112957B2 (en) * 2014-10-22 2018-10-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US20180134683A1 (en) 2015-05-07 2018-05-17 Teligene Ltd. Heterocylcic compounds as idh2 inhibitors

Also Published As

Publication number Publication date
DOP2021000030A (es) 2021-05-31
RU2760184C1 (ru) 2021-11-22
CN112638910A (zh) 2021-04-09
PH12021550329A1 (en) 2021-10-04
BR112021003652B1 (pt) 2022-04-26
US20220064155A1 (en) 2022-03-03
EP3845530A1 (en) 2021-07-07
CN112638910B (zh) 2024-06-11
AU2019331328A1 (en) 2021-03-11
JP7162741B2 (ja) 2022-10-28
TN2021000025A1 (en) 2022-10-03
CA3108856A1 (en) 2020-03-05
CL2021000421A1 (es) 2021-07-23
EP3845530A4 (en) 2022-04-27
CA3108856C (en) 2023-05-16
BR112021003652A2 (pt) 2021-05-18
KR102328682B1 (ko) 2021-11-18
AU2019331328B2 (en) 2022-03-17
BR122022001938B1 (pt) 2022-04-19
MA53507A (fr) 2022-04-27
SG11202101451QA (en) 2021-03-30
CO2021001849A2 (es) 2021-02-26
JP2021534256A (ja) 2021-12-09
ECSP21011232A (es) 2021-03-31
KR20200024111A (ko) 2020-03-06
PE20210417A1 (es) 2021-03-04

Similar Documents

Publication Publication Date Title
MX2021002188A (es) Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.
CR20200520A (es) Compuestos heterocíclicos como inmunomoduladores
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
TN2016000581A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
MX2010006421A (es) Compuestos organicos.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2020002449A (es) Nuevos compuestos heterociclicos fungicidas.
PH12018502012A1 (en) Griseofulvin compound
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
PH12020550905A1 (en) Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
MX2020000576A (es) Compuestos quimicos.
MX2021014680A (es) Derivado de benzotriazol.
MX2021003427A (es) Nuevos oxadiazoles.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
WO2015042414A8 (en) Multicyclic compounds and methods of using same
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
ZA202206266B (en) Pd-l1 antagonist compound